Tag: GlobeNewswire

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC | OTCQB: ZCTSF | FRA: 7TV) (“Zacatecas Silver” or the “Company”) is pleased to announce that it has entered into an option agreement (the “Agreement”) with Guanajuato Silver Company Ltd. (TSXV: GSVR) (“Guanajuato Silver”) and its subsidiary Mina Bolanitos, S.A. de C.V. (“Mina Bolanitos”), under which the Company may acquire a 100% interest in the Lourdes gold-silver project (“Lourdes” or the “Project”) in Guanajuato State, Mexico. Lourdes is a low sulphidation epithermal vein system in a historical mining district that has seen only seven shallow drill holes.

Highlights

• Low sulphidation epithermal gold-silver vein system in a historical mining district, with at least six mapped vein structures across three concessions totalling 509 hectares.
• The El Tigre vein, the principal target, has been mapped over approximately 770 metres of strike at surface with widths of 0.35 to 6.0 metres. A silicified footwall stockwork zone measures approximately 400 metres long and 15 to 30 metres wide.
• The only drilling on the Project consists of seven shallow core holes totalling 1,424 metres completed in 2003–2004, which had poor core recovery in the vein zones. Previous operators interpreted the system as exposed at a high epithermal level, with the deeper portions of the veins untested.
• Total consideration of US$825,000 over two years, comprising US$225,000 in cash and US$600,000 in common shares, with no minimum exploration expenditure commitments.
• The Project is located approximately 40 km northeast of Guanajuato City, with access by highway and dirt road.

Project Overview

Lourdes is located near the community of Buenavista del Cubo in the municipality of San Felipe, Guanajuato, approximately 18 km southeast of the town of San Felipe, within the El Cubo mineralized district of the Sierra del Cubo. The Project comprises three mining concessions totalling 509 hectares (Table 1).

Concession	Title No.	Date of Issuance	Expiry	Hectares
Lulú 5	215353	February 18, 2002	February 18, 2052	82.00
Lulú 7	215354	February 18, 2002	February 18, 2052	139.00
Buenavista	222243	June 17, 2004	June 17, 2054	288.00
Total				509.00

Table 1: Lourdes Project Mining Concessions

Geology and Historical Work

Lourdes hosts a low sulphidation epithermal vein system in Tertiary rhyolites. The veins strike northwest-southeast and dip steeply to the southwest. The principal mapped structures are the El Tigre, El PP, La Ordeñita, La Blanca, Tigre del Alto and El Lince veins. Vein textures include chalcedonic, banded, bladed and brecciated quartz, which previous operators interpreted as indicating a high level in the epithermal system.

Small-scale underground mining took place in the district between approximately 1906 and 1923. Several historical shafts remain on the Project and are currently flooded or inaccessible.

In 2003 and 2004, Minera Hochschild drilled seven core holes totalling 1,424 metres, testing the El Tigre, Tigre del Alto, El PP, La Ordeñita and Minas Viejas veins to approximately 100 to 150 metres below surface. Results were low grade, with the best intercept returning 0.7 g/t gold and 82 g/t silver over 0.4 metres core length in the El Tigre vein. Core recovery in the vein zones was reported to be below 50%. A subsequent review of the core by Endeavour Silver Corp. (“Endeavour”), who previously held the concessions, concluded that the El Tigre holes did not intersect the footwall stockwork zone.

Between 2012 and 2013, Endeavour completed geological mapping over 157.5 hectares, including detailed mapping of the El Tigre and El PP structures, collected 1,093 rock chip samples, and completed trenching along the El Tigre, El Lince, El PP and La Ordeñita veins. Rock chip results ranged from below detection to 39.9 g/t gold and from below detection to 378 g/t silver. Samples from the El Tigre footwall stockwork returned 0.015 to 3.91 g/t gold. Endeavour recommended a first-phase drill program on the El Tigre vein targeting depths below the historical drilling.

Rock chip samples are selective by nature and may not be representative of the grade of the mineralization. The historical drill and sample results described above were generated by previous operators, have not been verified by the Company, and should not be relied upon.

Planned Work

The Company plans to compile and review all historical data, including drill core and assay records where available, carry out confirmation sampling of the El Tigre vein and footwall stockwork, and refine drill targets to test the veins below the depth of the historical drilling.

CEO Quote

“With Lourdes, our strategy is taking shape,” said Eric Vanderleeuw, Chief Executive Officer and Director. “We’re building a pipeline of near-term drill targets – Oso Negro, Cumaro and now Lourdes – where a single discovery could change the scale of this Company. Lourdes has the ingredients we look for: historical mining, a mapped vein system with grade at surface, and almost no meaningful drilling. Behind all of it we have two mineral resources, at Panuco and Esperanza. That’s what separates us from other explorers our size: a resource base that holds value, and a pipeline built to generate steady news and real discovery potential. Seeing this strategy come together is exciting, and we’re just getting started. We’re moving quickly, executing on every front, and staying focused on what creates value in this business: getting the drill bit on good targets.”

Terms of the Agreement

To exercise the option and acquire a 100% interest in Lourdes, the Company must pay Mina Bolanitos a total of US$225,000 in cash and issue to Guanajuato Silver (or its nominee) US$600,000 in common shares of the Company (the “Consideration Shares”) as follows (Table 2):

Date	Cash	Consideration Shares
TSX Venture Exchange approval	US$75,000	US$200,000
First anniversary	US$75,000	US$200,000
Second anniversary	US$75,000	US$200,000
Total	US$225,000	US$600,000

Table 2: Option Payment Schedule

The Consideration Shares issuable on TSX Venture Exchange approval will be issued at the Market Price, as defined in the policies of the TSX Venture Exchange. The Consideration Shares issuable on the first and second anniversaries (the “Deferred Shares”) will be issued at a price equal to the greater of (i) the Market Price on the date of announcement of the transaction, less the maximum discount permitted by the TSX Venture Exchange, and (ii) the 10-day volume weighted average price (“VWAP”) immediately prior to issuance, with any resulting shortfall in value between the VWAP and the Market Price payable in cash. All Consideration Shares will be subject to a statutory hold period of four months and one day from the date of issuance. The Company may accelerate the option payments at its discretion.

During the option period, the Company will be the operator of the Project and will be responsible for all costs of maintaining the concessions in good standing.

On exercise of the option, the Company will grant Mina Bolanitos a 2.0% net smelter return (“NSR”) royalty, of which 1.0% may be purchased by the Company for US$1,000,000 at any time prior to the commencement of production. The Project is also subject to an existing 3.0% NSR royalty, of which 2.0% may be purchased for US$2,000,000.

The Agreement is subject to the acceptance of the TSX Venture Exchange. No finder’s fees are payable in connection with the transaction. The transaction is an arm’s length transaction.

Historical Data

The historical information in this news release is derived from internal reports prepared by previous operators, including Endeavour (2013) and Minera Hochschild (2004). Endeavour rock chip samples were analyzed by ALS Chemex in Zacatecas by atomic absorption (Au-AA23) and inductively coupled plasma (ME-ICP41) methods. The Company has not independently verified the sampling methods, analytical procedures or quality assurance and quality control programs used by previous operators, and a Qualified Person has not done sufficient work to verify the historical information. The Company is not treating this information as current.

Qualified Person
The technical information in this news release has been reviewed and approved by Chris Wilson, B.Sc. (Hons), PhD, FAusIMM (CP), FSEG, FGS, Chief Geologist of Zacatecas Silver. Dr. Wilson is a Qualified Person as defined by NI 43-101 and is not independent due being Chief Geologist and a director.

About Zacatecas Silver Corp.

Zacatecas Silver is a multi-asset precious metals exploration company with a portfolio of six projects across Mexico, spanning Zacatecas, Sonora, Morelos, and Oaxaca, and has entered into an option to acquire the Lourdes project in Guanajuato.

The Zacatecas Silver Project is located in Zacatecas State, within the highly prospective Fresnillo silver belt, which has produced over 6.2 billion ounces of silver. The Company holds 7,826 hectares of ground prospective for low-sulphidation and intermediate-sulphidation silver-base metal mineralization. A Mineral Resource Estimate at the Panuco deposit comprises 3.41 million tonnes at 187 g/t AgEq for 20.5 million ounces AgEq (see news release dated May 31, 2023). The property is 25 km southeast of MAG Silver’s Juanicipio Mine and Fresnillo PLC’s Fresnillo Mine, and shares boundaries with Defiance Silver and Endeavour Silver.

Esperanza is an advanced stage, attractive low-cost, low-capital-intensity and low-technical-risk growth project located in Morelos state, Mexico. The Company announced a Mineral Resource Estimate at Esperanza consisting of a Measured and Indicated Mineral Resource Estimate of 45.4 million tonnes at 0.79 g/t AuEq (0.76 g/t gold and 8.5 g/t silver) for 1.15 million ounces AuEq (1.11 million ounces gold and 12.37 million ounces silver) and an Inferred Mineral Resource Estimate of 11.2 million tonnes at 0.57 g/t AuEq (0.53 g/t gold and 11.2 g/t silver) for 208 thousand ounces AuEq (190 thousand ounces gold and 4.02 million ounces silver) (see news release dated June 22, 2026).

The Company also holds four exploration properties in Sonora and Oaxaca. Oso Negro (Sonora) is an undrilled, high-grade low sulphidation epithermal system with multiple veins mapped over more than 3 km of strike length. Cumaro (Sonora) is situated along trend from Coeur Mining’s El Picacho development and hosts extensions of proven low sulphidation vein systems with high-grade channel sampling results. La Lola (Sonora) is a large, underexplored 1,183-hectare property anchored by the La Barra vein, a 5 km structure reaching up to 40 m in width. Ejutla (Oaxaca) comprises 10,603 hectares in the Taviche-Miahuatlán region near the former Fortuna Silver San José Mine, hosting multiple vein systems and alteration zones anomalous in gold, silver, and Carlin-style pathfinder elements. The Company has also entered into an option to acquire a 100% interest in Lourdes (Guanajuato), a 509-hectare low sulphidation epithermal gold-silver vein system with limited historical drilling.

On behalf of the Company
Eric Vanderleeuw
Chief Executive Officer and Director
(519) 729 2440

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Zacatecas Silver cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by many material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to Zacatecas Silver’s limited operating history, its proposed exploration and development activities on its mineral properties and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Zacatecas Silver does not undertake to publicly update or revise forward-looking information.

Forward-looking statements in this news release include, but are not limited to, statements regarding the acceptance of the Agreement by the TSX Venture Exchange, the completion of the option payments and issuance of the Consideration Shares, the exercise of the option, planned exploration at Lourdes, and the interpretation of historical exploration data. There can be no assurance that the Company will complete the option payments or exercise the option.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

To the Nasdaq Copenhagen

October 5, 2026

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 2 October 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Nykredit Realkredit A/S

Attachments

• Prepayments – Nykredit Realkredit A_S 05-10-2026
• eordindf

To the Nasdaq Copenhagen

October 5, 2026

Prepayments (CK93)

Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 2 October 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Totalkredit A/S

Attachments

• Prepayments – Totalkredit A_S 05-10-2026
• eordindftk

• €250,000 (approx. C$400,000) non-repayable grant
• Strong endorsement of economic potential and strategic importance of Escacena Project

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Pan Global Resources Inc. (“Pan Global” or the “Company”) (TSX-V: PGZ; OTCQB: PGZFF; FRA: 2EU) is pleased to announce that its wholly-owned Spanish subsidiary, Minera Sabina SLU, has been awarded a non-repayable grant of €250,000 (approx. C$400,000) from the General Directorate for Energy Policy and Mining, within the Spanish Ministry for Ecological Transition and the Demographic Challenge. The funding will be used to accelerate exploration within the Company’s 100%-owned Escacena Project (“Escacena”) in the Iberian Pyrite Belt in southern Spain.

Highlights:

• Non-Dilutive Funding: The €250,000 provides immediate, non-dilutive capital directly allocated to ground exploration at the Escacena Project
• Validation: The grant selection underlines the economic potential and strategic importance of the Escacena Project to the regional economy
• Targeted Work: Funding will specifically support upcoming work, including cartography, soil sampling, geophysical surveys and diamond drilling, scheduled to begin immediately

“We are grateful to the General Directorate for Energy Policy and Mining for their strong endorsement and financial support. The grant initiative, along with other programs, highlights a strong commitment to the mining sector in Spain to secure critical metals for future economic growth,” said Tim Moody, President and CEO of Pan Global Resources. “This investment allows us to accelerate our exploration timeline at Escacena and progress our core targets without dilution to our shareholders.”

The award to Pan Global highlights Spain’s longstanding commitment to the exploration industry which is vital to expanding its critical mineral endowment through new discoveries. The 14,753-hectare Escacena Project is Pan Global’s flagship asset. To date, two deposits have been discovered at Escacena North and the highly prospective Escacena South property hosts more than a dozen geophysical targets for investigation. Testing of the highest priority targets at Escacena South will commence as soon as the required permits are received.

Current Exploration Activities

Drilling is currently underway to expand the Cañada Honda mineral resource at Escacena North. Geophysics, geochemical sampling, and geological programs are also continuing across Escacena North to identify additional drill targets. Results for the first of the drillholes from this year’s program at Cañada Honda will be announced when available.

A helicopter electromagnetic and magnetic survey has recently been completed at the highly prospective Escacena South property. Advanced interpretation of the survey results is aiding drill target definition. Results of the survey will be released as soon as interpretation is completed.

A drill rig is also currently operating at the Company’s Cármenes Project in northern Spain, testing the Providencia target.

About Pan Global Resources

Pan Global Resources Inc. is actively exploring for copper-rich mineral deposits along with gold and other metals. Copper has compelling supply-demand fundamentals and outlook for strong long-term prices as a critical metal for global electrification and energy transition. Gold also attracted record prices in 2026.

The Company’s flagship Escacena Project, hosting La Romana and Cañada Honda copper-tin-gold mineral resources, is in the prolific mining area known as the Iberian Pyrite Belt in southern Spain, where a favourable permitting track record, excellent infrastructure, mining and professional expertise, and support for copper as a Strategic Raw Material by the European Commission collectively define a tier-one low-risk jurisdiction for mining investment.

The Company’s second project, at Cármenes in northern Spain, is an area with a long mining history and excellent infrastructure. The Company has recently made a new gold discovery at the first of many targets to be investigated in this project area.

The Pan Global team comprises proven talent in exploration, discovery, development, and mining operations. Pan Global Resources is committed to operating safely and with utmost respect for the environment and our partnered communities. The Company is a member, and operates under the principles, of the United Nations Global Compact.

Qualified Persons

Álvaro Merino, Vice President Exploration for Pan Global Resources and a qualified person as defined by National Instrument 43-101, has approved the scientific and technical information for this media release. Mr. Merino is not independent of the Company.

To learn more about Pan Global Resources, please visit the Company’s Curation Connect Pan Global showcase and explore AI-generated responses to your enquiries.

FOR MORE INFORMATION PLEASE CONTACT:
Jason Mercier, VP Investor Relations and Communications
jason@panglobalresources.com / investors@panglobalresources.com
Tel: +1-236-886-9518
www.panglobalresources.com

Forward-looking statements

Statements which are not purely historical are forward-looking statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. This news release contains forward-looking statements, including statements regarding planned exploration activities, the potential to verify or convert historical mineral resource estimates, and the potential size or continuity of mineralization at the Project. Forward-looking statements are subject to risks and uncertainties that could cause actual outcomes and the Company’s actual results to differ materially from those in such forward-looking statements, including risks related to exploration results, the ability to verify historical data, permitting, financing, commodity prices, and general economic conditions. The Company believes that the expectations reflected in the forward-looking information included in this media release are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Risks and uncertainties include, but are not limited to, economic, competitive, governmental, environmental, and technological factors that may affect the Company’s operations, markets, products, and prices. Readers should refer to the risk disclosures outlined in the Company’s Management Discussion and Analysis of its audited financial statements filed with the British Columbia Securities Commission.

The forward-looking information contained in this media release is based on information available to the Company as of the date of this media release. Except as required under applicable securities legislation, the Company does not intend, and does not assume any obligation, to update this forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Transaction in Own Shares

October 02, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 02 October 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
02/10/2026	950,000	£ 36.2500	£ 35.6750	£ 35.9922	LSE	GBP
02/10/2026	–	–	–	–	Chi-X (CXE)	GBP
02/10/2026	–	–	–	–	BATS (BXE)	GBP
02/10/2026	475,000	€ 42.7400	€ 42.0750	€ 42.4470	XAMS	EUR
02/10/2026	–	–	–	–	CBOE DXE	EUR
02/10/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026. 

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20261002_Shell RNS – full version

   Heineken Holding N.V. reports transactions under its current

share buyback programme

Amsterdam 5 October 2026 – Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026.

From 28 September 2026 up to and including 2 October 2026 a total of 164,528 shares were repurchased on exchange at an average price of €65.68.

Up to and including 2 October 2026, a total of 4,072,185 shares were repurchased under the second tranche of the share buyback programme for a total consideration of €267,322,120.

Heineken Holding N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.heinekenholding.com/investors/share-information/share-buyback-programme

Enquiries

Media Heineken Holding N.V.
Kees Jongsma
tel. +31 6 54 79 82 53
E-mail: cjongsma@spj.nl
Media		Investors
Christiaan Prins		Tristan van Strien
Director of Global Communications		Global Director of Investor Relations
Marlie Paauw		Lennart Scholtus / Chris Steyn
Global Media Lead		Investor Relations Manager / Senior Analyst
E-mail: pressoffice@heineken.com		E-mail: investors@heineken.com
Tel: +31-20-5239355		Tel: +31-20-5239590

Regulatory information:
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company. HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, HEINEKEN brews the joy of true togetherness to inspire a better world. HEINEKEN’s dream is to shape the future of beer and beyond to win the hearts of consumers. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. HEINEKEN operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on www.heinekenholding.com and www.theheinekencompany.com and follow HEINEKEN on LinkedIn and Instagram.

Attachment

• 20261005 HHNV SBB Weekly update 28 September 2026 – 2 October 2026

Experienced U.S. gold operator with large-scale open-pit operations, mine start-up and capital management expertise

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) (“Liberty Gold” or the “Company”) is pleased to announce the appointment of Curtis Cadwell as General Manager for its run-of mine (“ROM”), heap leach Black Pine Oxide Gold Project (“Black Pine” or the “Project”) in southeastern Idaho, effective October 12, 2026. The appointment further strengthens Liberty Gold’s mine operating capability as the Company advances detailed engineering and permitting at Black Pine and fills a key role in the operating team required for successful design, construction and future production.

Mr. Cadwell brings three decades of mining industry experience, spanning mine operations, project ramp-up, life-of-mine planning, capital allocation, cost control and senior finance management, with extensive experience across major gold operations in the United States (“U.S.”). Mr. Cadwell spent more than 20 years with Barrick Gold Corporation in progressively senior operating and financial roles. As General Manager, Operations for Barrick Nevada, he was responsible for the Goldstrike and Cortez operations, encompassing open-pit and underground mining, processing, resource development, technical services, supply chain functions and a workforce of approximately 2,500.

Most recently, Mr. Cadwell served as Finance Manager, Nevada for Kinross Gold Corporation, supporting the Round Mountain and Bald Mountain open pit, ROM leach gold operations with responsibility for budgeting, life-of-mine planning, continuous improvement, purchasing, warehousing and cost optimization. Previously, he served as Operations and Finance Manager at McEwen Mining Inc.’s Gold Bar operation and as Mine Manager and Director of Operations at OceanaGold Corporation’s Haile Gold Mine, where he was responsible for the transition of the operation from startup into an operating site. Mr. Cadwell holds a BBA in Accounting and Finance from the University of New Mexico and is a Certified Public Accountant.

“Curtis brings an exceptional combination of large-scale U.S. gold operating experience and financial discipline into the growing Liberty Gold team,” said Jon Gilligan, President and CEO of Liberty Gold. ”He has managed complex mining operations, mine ramp-ups and life-of-mine planning and he understands the importance of delivering mine production safely with rigorous cost and capital control. As detailed engineering and permitting advance at Black Pine, Curtis is a key addition to the team we are building to take us through disciplined project development and fully prepared to execute a build safely and efficiently, subject to a construction decision and the necessary federal and state permits.”

Commenting on joining Liberty Gold, Mr. Cadwell stated: “I am very excited to become part the Liberty Gold team at Black Pine. It is an exceptional U.S. gold project and the opportunity to take a key role in building a new mine in a strong mining district is incredibly appealing. Black Pine’s scale, anticipated mine life and production potential create an opportunity to establish an operation that can provide lasting value to surrounding communities and contribute meaningfully to Idaho’s development.”

ABOUT LIBERTY GOLD

Liberty Gold is a U.S.-focused gold company advancing Black Pine, its 100% owned oxide gold project in Idaho, located within the Great Basin, one of the world’s most productive and mining-friendly gold regions. Black Pine is a large-scale, past-producing, run-of-mine heap leachable gold deposit advancing through permitting toward a potential construction decision. The Company’s strategy is centered on advancing high-quality, long-life gold assets, with a clear focus on technical simplicity, strong environmental performance, project executability, collaborative permitting processes, and value creation. This reflects Liberty Gold’s commitment to the discipline of delivery. The Company is led by an experienced team with a track record of discovery, development, and delivering sustained long-term value.

For more information, visit libertygold.ca or contact:

Susie Bell, Vice President, Investor Relations and Corporate Communications
Phone: 604-632-4677 or Toll Free 1-877-632-4677
info@libertygold.ca

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws, including statements or information concerning future financial or operating performance of Liberty Gold and its business, operations, properties and condition; planned de-risking activities at Liberty Gold’s mineral properties; federal and state permitting timelines; the advancement of the Black Pine Project through feasibility and permitting; the completion of Centerra Gold Inc.’s subscription for common shares pursuant to its top-up right; future updates to mineral resources; the potential quantity, recoverability and/or grade of minerals; the potential size of a mineralized zone or potential expansion of mineralization; proposed exploration and development of Liberty Gold’s mineral property interests; future water rights acquisitions; the results of mineral resource estimates, mineral reserve estimates, preliminary feasibility studies or feasibility studies; and the Company’s anticipated expenditures.

Forward-looking information is often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan”, “continue”, “planned”, “expect”, “project”, “predict”, “potential”, “targeting”, “intends”, “believe”, “goal” and similar expressions, or variations of such words and phrases, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management as of the date the statements are made, including, among others, assumptions regarding future prices of gold and other metals, currency exchange rates and interest rates, favourable operating conditions, political stability, timely receipt of governmental, regulatory and stock exchange approvals, completion of the issuance of common shares to Centerra Gold Inc. pursuant to its top-up right on the terms described herein, receipt of financing on time, obtaining renewals for existing licences and permits and obtaining required licences and permits, labour stability, stability in market conditions, availability of equipment, results or timing of any mineral resources, mineral reserves, baseline studies, resource conversion, pre-feasibility studies or feasibility studies, the availability of drill rigs, successful resolution of disputes and anticipated costs and expenditures. Many assumptions are based on factors and events that are not within the control of Liberty Gold and there is no assurance they will prove to be correct.

Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from any future results expressed or implied by such forward-looking information, including risks related to the interpretation of results and/or reliance on technical information provided by third parties as related to the Company’s mineral property interests; changes in project parameters as plans continue to be refined; current economic conditions; state and federal permitting processes; future prices of commodities; possible variations in grade or recovery rates; the costs and timing of the development of new deposits; failure of equipment or processes to operate as anticipated; the failure of contracted parties to perform; the timing and success of exploration activities generally; the timing or results of the publication of any mineral resources, mineral reserves or feasibility studies; delays in permitting; possible claims against the Company; labour disputes and other risks of the mining industry; delays in obtaining governmental, regulatory or stock exchange approvals, financing, or completing the issuance of common shares to Centerra Gold Inc. pursuant to its top-up right; timing of the completion of exploration; and those factors discussed in the Annual Information Form of the Company dated March 25, 2026, in the section entitled “Risk Factors”, under Liberty Gold’s SEDAR+ profile at www.sedarplus.ca.

Although Liberty Gold has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Liberty Gold disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except for material differences between actual results and previously disclosed material forward-looking information, or as otherwise required by law.

Except for statements of historical fact, information contained herein or incorporated by reference herein constitutes forward-looking statements and forward-looking information. Readers should not place undue reliance on forward-looking information. All forward-looking statements and forward-looking information attributable to Liberty Gold are expressly qualified by these cautionary statements.

HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) announced today that it will host a conference call to discuss its third quarter financial results on October 29, 2026, at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). The company plans to issue its third quarter 2026 earnings release and earnings presentation in advance of the call. Both will be available on KBR’s website.

The conference call will be webcast simultaneously through the Investor Relations section of KBR’s website at investors.kbr.com. A replay of the webcast will be available after the call on our website via the webcast link here: https://events.q4inc.com/attendee/485891893.

About KBR
KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle.

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries.

About Trinzic
KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.    

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

• $12.00 per share Purchase Price, represents a 14% premium to Athabasca’s 20-day volume-weighted average trading price 
• Transaction consideration mix of 35% Cenovus shares and 65% cash; Athabasca shareholders may elect to receive all cash, all Cenovus shares or any combination of the two, allowing them to tailor elections to their individual investment preferences, subject to pro-ration under the Arrangement
• $5.7 billion enterprise value with compelling metrics¹ of $127,000 per boe/d and 10.2x Debt Adjusted Funds Flow, recognizing the industry-leading value creation by Athabasca
• 25% premium to Athabasca’s Proved plus Probable After-Tax Net Asset Value², accelerating value capture from future growth plans
• Participation in upside to an increased and accelerated development plan of Athabasca’s McMurray thermal and Duvernay assets with exposure to Cenovus’s diverse top-tier energy portfolio
• Substantial synergies from close asset proximity and Cenovus’s leading in-situ expertise and scale in the McMurray fairway. Cenovus’s broader integrated platform and scale are better positioned to manage ongoing fiscal, regulatory and market-access risks

CALGARY, Alberta, Oct. 05, 2026 (GLOBE NEWSWIRE) — Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to announce that it has entered into a definitive arrangement agreement (the “Agreement”) with Cenovus Energy Inc. (“Cenovus”), pursuant to which Cenovus will acquire all of the issued and outstanding common shares of Athabasca (the “Athabasca Shares”) for $12.00 per Athabasca Share (the “Purchase Price”) in a cash-and-share transaction (the “Transaction”). The Transaction implies an equity value for Athabasca of approximately $5.8 billion and is expected to close in December 2026.

“We are immensely proud of what the Athabasca team has built. Through disciplined operational execution, prudent capital allocation and an unwavering focus on per-share value creation, we have transformed Athabasca over the past decade into a financially strong company with a deep portfolio of high-quality assets and delivered exceptional returns for our shareholders,” said Rob Broen, President and Chief Executive Officer of Athabasca.

“This Transaction recognizes the value our team has created and allows Athabasca shareholders to realize substantial value today, with the opportunity to participate in future upside through Cenovus shares. Cenovus is the right long-term operator for these assets, with the scale, financial capacity, technical expertise and proven execution record to accelerate their development and realize their long-term potential. This outcome reflects the commitment and execution of our employees, and I want to thank every member of the Athabasca team for their contribution to our success.”

Strategic Rationale

• Compelling Value and Transaction Metrics: The $12.00 per share consideration, represents a 14% premium to Athabasca’s 20-day volume-weighted average price using the 0.264 share exchange ratio (see Transaction Details). The Transaction implies compelling metrics¹ of $127,000 per boe/d and 10.2x Debt Adjusted Funds Flow based on Athabasca management’s forecasts. These metrics compare well with historical corporate energy transactions.
• Recognition of Exceptional Shareholder Value Creation: The Transaction recognizes the substantial value created by Athabasca, as demonstrated by total shareholder return exceeding 1,000% over the past five years.
• Flexible Consideration with Value Certainty and Continued Upside: The aggregate consideration mix of 65% cash and 35% equity provides Athabasca shareholders with near-term liquidity and value certainty, together with continued upside exposure to Cenovus’s broader portfolio of leading in-situ assets including Christina Lake, Foster Creek and Sunrise in the McMurray fairway. Athabasca shareholders have additional election flexibility to prioritize near-term value crystallization, continued participation in future value creation across Cenovus’s in-situ and integrated portfolio or a combination of both.
• Meaningful Premium to Athabasca’s After-Tax Net Asset Value: The Purchase Price represents a premium of 25% to Athabasca’s Proved plus Probable After-Tax Net Asset Value². Athabasca shareholders will receive significant and immediate recognition of the value embedded in Athabasca’s standalone growth plans, including the Leismer expansion, Corner development and Duvernay Energy.
• Accelerated Development of Athabasca’s Deep Thermal Resource Portfolio: Athabasca’s extensive, long-life Thermal resource portfolio (1.2 billion barrels Proved plus Probable reserves and 1 billion barrels Best Estimate Contingent Resource) will benefit from increased and accelerated development under Cenovus’s ownership. Cenovus brings an investment-grade balance sheet, leading in-situ operating and development expertise, diversified market access and a proven track record of successfully executing and operating large-scale thermal oil projects. Specifically, Corner Phases 2 and 3 and further Leismer expansions are expected to be accelerated relative to the timelines contemplated in Athabasca’s standalone plan.
• Synergies: Consolidating Cenovus and Athabasca assets in the McMurray fairway is expected to generate significant operational and development synergies to enhance asset value. Cenovus’s leading in-situ expertise and scale position it to execute a broader growth strategy in which Athabasca shareholders can participate through their Cenovus shares. Its integrated platform and scale are better positioned to manage ongoing fiscal, regulatory and market-access risks.
• Duvernay Consolidation: Cenovus and Athabasca are currently equity partners in Duvernay Energy Corporation. The Transaction consolidates ownership of Duvernay Energy Corporation under Cenovus, simplifies development planning and complements Cenovus’s conventional business. Cenovus will be able to accelerate development, utilizing its strong balance sheet to drive growth and capture value in these top-tier assets.

Footnote: Refer to the “Reader Advisory” section within this news release for additional information on Non‐GAAP Financial Measures.
Notes: 1. Metrics based on enterprise value to Athabasca management’s 2026 exit production and Debt Adjusted Funds Flow forecast. 2026 strip commodity prices (Sept. 28): US$85 WTI, US$15.50 Western Canadian Select heavy differential, C$1.80 AECO, 0.72 C$/US$ FX. 2. Net Asset Value per Share calculated as McDaniel’s Proved plus Probable after-tax NPV10, as at December 31, 2025, adjusted for Net Cash as at June 30, 2026, and the Duvernay Energy minority interest divided by common shares.

Transaction Details 

The Transaction will be completed by way of a plan of arrangement (the “Arrangement”) under the Business Corporations Act (Alberta) (the “ABCA”).

Under the terms of the Arrangement, Cenovus will acquire all of the issued and outstanding Athabasca Shares for cash and share consideration currently valued at $12.00 per Athabasca Share (the “Purchase Price”). Athabasca shareholders will have the option to elect to receive (i) $12.00 in cash for each Athabasca Share held; (ii) 0.264 of a Cenovus share for each Athabasca Share held; or (iii) such other proportion of cash and Cenovus shares as specified by the Athabasca shareholder. Shareholders who do not make a valid election will be deemed to have elected to receive default consideration of 100% cash for their Athabasca Shares.

All elections (including deemed elections) will be subject to pro-ration and cash and Cenovus share maximums. The aggregate cash consideration will not exceed 75% of the total consideration payable under the Arrangement, and the aggregate share consideration will not exceed 35% of the total consideration payable under the Arrangement. Accordingly, the aggregate total consideration will comprise between 65% and 75% cash and between 25% and 35% Cenovus shares, based on elections made and deemed to be made. Depending on a particular shareholder’s election or deemed election and pro-rationing, an Athabasca shareholder may ultimately receive entirely cash, entirely Cenovus shares or a combination of both.

The Transaction requires approval by Athabasca’s shareholders at a special meeting of Athabasca shareholders to be called to consider and vote on the Transaction (the “Athabasca Meeting”). The Athabasca Meeting is expected to be held in late November 2026, with the Transaction expected to close in December 2026. Details of the Transaction and the required shareholder vote will be included in a management information circular (“Circular”) that Athabasca expects to mail to Athabasca shareholders and file on SEDAR+ (http://www.sedarplus.com) in early November 2026. All Athabasca shareholders are urged to read the Circular once available as it will contain additional important information concerning the Transaction, including the deadline for making elections to receive cash and/or Cenovus shares.

Completion of the Transaction is subject to certain conditions set forth in the Agreement, including, without limitation, receipt of Athabasca shareholder approval, approval of the Court of King’s Bench of Alberta, applicable regulatory and stock exchange approvals, including under the Competition Act (Canada), and other customary closing conditions.

All of the directors and executive officers of Athabasca have entered into voting support agreements with Cenovus pursuant to which they have agreed, subject to the terms thereof, to vote their Athabasca Shares in favour of the resolutions approving the Transaction.

Recommendation of the Athabasca Board of Directors

The board of directors of Athabasca (the “Athabasca Board”), based in part upon the unanimous recommendation of the Special Committee of the Athabasca Board formed to consider the Transaction (the “Special Committee”) and after seeking and carefully considering advice from its financial and legal advisors, has unanimously determined that the Transaction is in the best interests of Athabasca and is fair to Athabasca shareholders. The Athabasca Board has determined to unanimously recommend that Athabasca shareholders vote in favour of the resolutions approving the Transaction and related matters at the Athabasca Meeting.

Advisors and Fairness Opinions

Peters & Co. Limited (“Peters & Co.”) is acting as exclusive financial advisor to the Company and the Athabasca Board. Peters & Co. has provided a verbal opinion to the effect that, as of the date of such opinion and based upon and subject to the assumptions, limitations and qualifications set forth therein, the consideration to be received by Athabasca shareholders pursuant to the Transaction is fair, from a financial point of view, to Athabasca shareholders.

National Bank of Canada Capital Markets is acting as financial advisor to the Special Committee and has provided a verbal opinion to the Special Committee that, as of the date of such opinion and based upon and subject to the assumptions, limitations and qualifications set forth therein, the consideration to be received by Athabasca shareholders pursuant to the Transaction is fair, from a financial point of view, to Athabasca shareholders.

Norton Rose Fulbright Canada LLP is acting as legal counsel to the Company. Bennett Jones LLP is acting as independent legal counsel to the Special Committee.

About Athabasca Oil Corporation

Athabasca Oil Corporation is a Canadian energy company with a focused strategy on the development of thermal and light oil assets. Situated in Alberta’s Western Canadian Sedimentary Basin, the Company has amassed a significant land base of extensive, high-quality resources. Athabasca’s light oil assets are held in a private subsidiary (Duvernay Energy Corporation) in which Athabasca owns a 70% equity interest. Athabasca’s common shares trade on the TSX under the symbol “ATH”. For more information, visit www.atha.com.

For more information, please contact:
Matthew Taylor	Robert Broen
Chief Financial Officer	President and CEO
1-403-817-9104	1-403-817-9190
mtaylor@atha.com	rbroen@atha.com

Reader Advisory:

This News Release contains forward-looking information that involves various risks, uncertainties and other factors. All information other than statements of historical fact is forward-looking information. The use of any of the words “anticipate”, “plan”, “project”, “continue”, “maintain”, “may”, “estimate”, “expect”, “will”, “target”, “forecast”, “could”, “intend”, “potential”, “guidance”, “outlook” and similar expressions suggesting future outcome are intended to identify forward-looking information. The forward-looking information is not historical fact, but rather is based on the Company’s current plans, objectives, goals, strategies, estimates, assumptions and projections about the Company’s industry, business and future operating and financial results. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. No assurance can be given that these expectations will prove to be correct and such forward-looking information included in this News Release should not be unduly relied upon. This information speaks only as of the date of this News Release. In particular, this News Release contains forward-looking information pertaining to, but not limited to, the following: the Purchase Price per Athabasca share to be received pursuant to the Transaction; the anticipated benefits of the Transaction to Athabasca shareholders, including but not limited to near-term liquidity and value certainty and participation in future upside of Cenovus; the anticipated timing for closing of the Transaction; the expectation that the Transaction reduces Athabasca shareholders’ exposure to future volatility associated with commodity prices, regulatory and fiscal policy, and the execution of Athabasca’s standalone growth plans; the expectations that the Transaction will bring forward substantial value from Athabasca’s standalone growth plans including the Leismer expansion, Corner development and Duvernay Energy; the anticipated accelerated development of Athabasca’s assets under Cenovus’s ownership, including the advancement of Corner Phases 2 and 3 and further Leismer expansions beyond the timelines contemplated in Athabasca’s standalone plans; the expectations that consolidating Cenovus and Athabasca assets in the McMurray fairway will generate significant operational and development synergies to enhance asset value; the expectations that the consolidated ownership of Duvernay Energy under Cenovus as a result of the Transaction will simplify development planning, accelerate development, drive growth, capture value and complement Cenovus’s conventional business; the anticipated timing for holding of the Athabasca Meeting; the expected timing of the mailing and contents of the Circular; and other similar statements.

In addition, information and statements in this News Release relating to “Reserves” and “Resources” are deemed to be forward-looking information, as they involve the implied assessment, based on certain estimates and assumptions, that the reserves and resources described exist in the quantities predicted or estimated, and that the reserves and resources described can be profitably produced in the future. With respect to forward-looking information contained in this News Release, assumptions have been made regarding, among other things: the timely completion of the Transaction and the satisfaction of the conditions to which the Transaction is subject to; the approval of the Transaction at the Athabasca Meeting; Athabasca’s standalone plan; regulatory and government approvals for the Transaction, including approval of the Court of King’s Bench of Alberta and receipt of applicable regulatory and stock exchange approvals, in each case on the anticipated timelines; the realization of anticipated benefits of the Transaction including significant operational and development synergies; commodity prices; the regulatory framework governing royalties, taxes and environmental matters in the jurisdictions in which the Company conducts and will conduct business and the effects that such regulatory framework will have on the Company, including on the Company’s financial condition and results of operations; the Company’s financial and operational flexibility; the Company’s financial sustainability; Athabasca’s cash flow break-even commodity prices; the Company’s ability to obtain qualified staff and equipment in a timely and cost-efficient manner; the applicability of technologies for the recovery and production of the Company’s reserves and resources; future capital expenditures to be made by the Company; future sources of funding for the Company’s capital programs; the Company’s future debt levels; future production levels; the Company’s ability to obtain financing and/or enter into joint venture arrangements, on acceptable terms as permitted under the Agreement; operating costs; compliance of counterparties with the terms of contractual arrangements; impact of increasing competition globally; collection risk of outstanding accounts receivable from third parties; geological and engineering estimates in respect of the Company’s reserves and resources; recoverability of reserves and resources; the geography of the areas in which the Company is conducting exploration and development activities and the quality of its assets. Certain other assumptions related to the Company’s Reserves and Resources are contained in the report of McDaniel & Associates Consultants Ltd. (“McDaniel”) evaluating Athabasca’s Proved Reserves, Probable Reserves and Contingent Resources as at December 31, 2025 (which is referred to herein as the “McDaniel Report”).

Actual results could differ materially from those anticipated in this forward-looking information as a result of significant known and unknown risks and uncertainties. Factors that could cause actual results to vary from forward-looking information or may affect the operations, performance, development and results of Athabasca’s businesses include: the risk that the Transaction may be varied, accelerated or terminated in certain circumstances; risks relating to the outcome of the Transaction, including the risks associated with approval at the Athabasca Meeting; the risk that the conditions to the Transaction may not be satisfied, or to the extent permitted, waived, including the risk that required regulatory approvals may not be received in a timely manner or at all; fluctuations in the market price of Cenovus shares and the resulting value of the share consideration; the risk that the anticipated benefits of the Transaction may not be realized in the manner or on the timelines anticipated or at all; weakness in the oil and gas industry; exploration, development and production risks; prices, markets and marketing; market conditions; trade relations and tariffs; climate change and carbon pricing risk; statutes and regulations regarding the environment; regulatory environment and changes in applicable law; gathering and processing facilities, pipeline systems and rail; reputation and public perception of the oil and gas sector; environment, social and governance goals; political uncertainty; state of capital markets; ability to finance capital requirements; access to capital and insurance; abandonment and reclamation costs; changing demand for oil and natural gas products; anticipated benefits of acquisitions and dispositions; royalty regimes; foreign exchange rates and interest rates; reserves; hedging; operational dependence; operating costs; project risks; supply chain disruption; financial assurances; diluent supply; third party credit risk; Indigenous claims; reliance on key personnel and operators; income tax; cybersecurity; advanced technologies; hydraulic fracturing; liability management; seasonality and weather conditions; unexpected events; internal controls; evolving corporate governance, sustainability and reporting framework; limitations of insurance; litigation; natural gas overlying bitumen resources; competition; chain of title and expiration of licenses and leases; breaches of confidentiality; new industry related activities or new geographical areas; water use restrictions and/or limited access to water; relationship with Duvernay Energy Corporation; management estimates and assumptions; third-party claims; conflicts of interest; inflation and cost management; credit ratings; growth management; impact of pandemics; ability of investors resident in the United States to enforce civil remedies in Canada; and risks related to Athabasca’s debt and securities. All subsequent forward-looking information, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Further information regarding the assumptions and risks inherent in the making of forward-looking statements and in respect of the Transaction will be found in the Circular, along with Athabasca’s other public disclosure documents, including the Company’s Annual Information Form dated March 4, 2026, which are available on SEDAR+ at www.sedarplus.ca.

Also included in this News Release are estimates of Athabasca’s 2026 production and Debt Adjusted Funds Flow, which are based on the various assumptions as to production levels, commodity prices, currency exchange rates and other assumptions disclosed in this News Release. To the extent any such estimate constitutes a financial outlook, it was approved by management and the Board of Directors of Athabasca and is included to provide readers with an understanding of the Company’s outlook. Management does not have firm commitments for all of the costs, expenditures, prices or other financial assumptions used to prepare the financial outlook or assurance that such operating results will be achieved and, accordingly, the complete financial effects of all of those costs, expenditures, prices and operating results are not objectively determinable. The actual results of operations of the Company and the resulting financial results may vary from the amounts set forth herein, and such variations may be material. The outlook and forward-looking information contained in this News Release were made as of the date of this News Release and the Company disclaims any intention or obligations to update or revise such outlook and/or forward-looking information, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law.

Oil and Gas Information

“BOEs” may be misleading, particularly if used in isolation. A BOE conversion ratio of six thousand cubic feet of natural gas to one barrel of oil equivalent (6 Mcf: 1 bbl) is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. As the value ratio between natural gas and crude oil based on the current prices of natural gas and crude oil is significantly different from the energy equivalency of 6:1, utilizing a conversion on a 6:1 basis may be misleading as an indication of value.

Reserves Information

The McDaniel Report was prepared using the assumptions and methodology guidelines outlined in the COGE Handbook and in accordance with National Instrument 51-101 Standards of Disclosure for Oil and Gas Activities, effective December 31, 2025. There are numerous uncertainties inherent in estimating quantities of bitumen, light crude oil and medium crude oil, tight oil, conventional natural gas, shale gas and natural gas liquids reserves and the future cash flows attributed to such reserves. The reserve and associated cash flow information set forth above are estimates only. In general, estimates of economically recoverable reserves and the future net cash flows therefrom are based upon a number of variable factors and assumptions, such as historical production from the properties, production rates, ultimate reserve recovery, timing and amount of capital expenditures, marketability of oil and natural gas, royalty rates, the assumed effects of regulation by governmental agencies and future operating costs, all of which may vary materially. For those reasons, estimates of the economically recoverable reserves attributable to any particular group of properties, classification of such reserves based on risk of recovery and estimates of future net revenues associated with reserves prepared by different engineers, or by the same engineers at different times, may vary. The Company’s actual production, revenues, taxes and development and operating expenditures with respect to its reserves will vary from estimates thereof and such variations could be material. Reserves figures described herein have been rounded to the nearest MMbbl or MMboe. For additional information regarding the consolidated reserves and information concerning the resources of the Company as evaluated by McDaniel in the McDaniel Report, please refer to the Company’s AIF.

Reserves Values (i.e., Net Asset Value) is calculated using the estimated net present value of all future net revenue from Athabasca’s reserves, before income taxes discounted at 10%, as estimated by McDaniel effective December 31, 2025 and based on average pricing of McDaniel, Sproule and GLJ as of January 1, 2026, and adjusted for Net Cash as at June 30, 2026 and the Duvernay Energy minority interest.

Non-GAAP and Other Financial Measures

“Debt Adjusted Funds Flow” is a financial measure contained in this News Release that does not have a standardized meaning prescribed by IFRS and is considered to be a non-GAAP financial measure. It is not intended to represent cash flow from operating activities, net earnings or other measures of financial performance calculated in accordance with IFRS. The Debt Adjusted Funds Flow measure allows management and others to evaluate the Company’s ability to fund its capital programs and meet its ongoing financial obligations using cash flow internally generated from ongoing operating related activities excluding interest costs related to debt instruments. This non-GAAP financial measure may not be comparable to similar measures presented by other issuers and should not be considered in isolation with measures that are prepared in accordance with IFRS. Net Cash is a supplementary financial measure.

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20^® (PCV20) and/or Capvaxive^® (PCV21)

Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and Older, All 28 VAX-31 Serotypes Shared with PCV20 and/or PCV21 Met Noninferiority Criterion at >0.667 Threshold; All Three Serotypes Unique to VAX-31 and Cross-Reactive Serotype 20B Met Superiority Criterion

Prespecified Primary Immunobridging Endpoint: Across All 32¹ Serotype Comparisons, VAX-31 Met Noninferiority Criterion at >0.667 Threshold in Adults Aged 18-49 Compared with Adults Aged 50-64

Prespecified Primary Safety Endpoint: VAX-31 Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied

Prespecified Individual Comparator Results: VAX-31 Met Noninferiority Criterion at >0.667 Threshold for 20 of 20 Serotypes Shared with PCV20 and 17 of 19 Shared with PCV21, and at Historical >0.5 Threshold, VAX-31 Met Noninferiority Criterion for 19 of 19 Shared with PCV21²

Company Expects to Report Results from OPUS-2 and OPUS-3 Adult Phase 3 Trials in First Half of 2027, Supporting Planned Biologics License Application Submission in First Half of 2028

Topline Results Further Validate Potential of Vaxcyte’s Carrier-Sparing Platform to Deliver Broader Coverage While Maintaining Magnitude of Immune Responses

Company to Host Webcast/Conference Call Today at 8:00 a.m. ET/5:00 a.m. PT

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. The results of OPUS-1 will serve as the cornerstone of a planned filing of a Biologics License Application (BLA), which will be subject to U.S. Food and Drug Administration (FDA) review.

In the OPUS-1 trial, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older:

• All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the prespecified noninferiority criteria (lower bound of the 95% confidence interval (LBCI) >0.667).³
  • For the 11 serotypes shared by VAX-31, PCV20 and PCV21, VAX-31 met all 11 primary noninferiority assessments based on opsonophagocytic activity (OPA) geometric mean ratios (GMRs). For each serotype, the prespecified analysis required noninferiority against one or both comparators, using an OPA GMR noninferiority criterion of LBCI >0.667 with prespecified multiplicity adjustment.³
  • For the nine serotypes only in VAX-31 and PCV20, all nine met the prespecified OPA GMR noninferiority criterion (LBCI >0.667).⁴
  • For the eight serotypes only in VAX-31 and PCV21, all eight met the prespecified OPA GMR noninferiority criterion (LBCI >0.667).⁴
• The three serotypes unique to VAX-31 and cross-reactive serotype 20B met the OPA GMR superiority criterion (LBCI >2.0) with prespecified multiplicity adjustment.³

For the prespecified primary immunobridging endpoint, VAX-31 met the noninferiority criterion (LBCI >0.667) for all 32¹ serotype OPA GMR comparisons in adults aged 18-49 compared to adults aged 50-64.

In the study, VAX-31 was well tolerated and demonstrated a safety profile similar to PCV20 and PCV21 at all ages studied.

In the prespecified individual comparator analyses, VAX-31 met the noninferiority criterion (LBCI >0.667) for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21. Compared to PCV21, serotypes 3 and 12F missed the LBCI >0.667 noninferiority criterion and met the historical LBCI >0.5 threshold.²

“We believe these positive OPUS-1 results provide clinical validation of our site-specific, carrier-sparing platform’s potential to deliver broader-spectrum pneumococcal vaccines while maintaining the magnitude of immune responses,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “VAX-31 met all prespecified primary immunogenicity endpoints across all age groups studied in this pivotal Phase 3 trial, providing the clinical cornerstone for our planned Biologics License Application. We believe VAX-31’s combination of broader coverage and robust immune responses, demonstrated in a trial inaugurating a more stringent noninferiority standard, sets a new benchmark for the class and gives us confidence in its potential for approval. We look forward to announcing results from OPUS-2 and OPUS-3 in the first half of 2027, to be followed by a manufacturing consistency study, as we work toward making this vaccine broadly available to help protect adults from the consequences of pneumococcal disease.”

“These OPUS-1 results strengthen our confidence in VAX-31’s potential to provide broader protection against invasive pneumococcal disease and pneumococcal pneumonia,” said James Wassil, Chief Scientific Officer and Chief Operating Officer of Vaxcyte. “Given current U.S. epidemiology, with the serotypes unique to PCV21 accounting for a larger share of adult disease, we expect the comparison of VAX-31 to PCV21 to be a particular focus of FDA review. PCV20 remains an important immunogenicity comparator for VAX-31, including for serotypes 4 and 19F, which are not contained in PCV21. We want to extend our gratitude to everyone involved in this program, especially the study participants, trial investigators and sites.”

“Important gaps remain in adult pneumococcal disease coverage, and OPUS-1 highlights VAX-31’s potential to address them,” said Luis Jodar, Ph.D., Chief Medical Officer of Vaxcyte. “Today’s adult PCVs differ in the serotypes they cover, requiring tradeoffs between coverage of currently circulating disease-causing serotypes and preserving coverage of historically important serotypes. VAX-31 is designed to bring both into a single 31-valent vaccine, with the potential to provide incremental coverage of 13-36% of invasive pneumococcal disease⁵ and 19-31% of pneumococcal pneumonia⁶ compared with currently available adult PCVs.”

About OPUS-1, the VAX-31 Adult Pivotal Phase 3 Trial
OPUS-1 is a randomized, double-blind, active-controlled Phase 3 trial evaluating the safety, tolerability and immunogenicity of the VAX-31 High Dose, the adult formulation being evaluated in the OPUS Phase 3 program, in healthy, pneumococcal-naïve⁷ U.S. adults aged 50 years and older (n=3,572), with a separate cohort of adults aged 18-49 years (n=475). In the High Dose formulation, all serotypes are dosed at 3.3 mcg, except serotypes 1, 5 and 22F, which are dosed at 4.4 mcg. The trial dosed 4,047 participants at approximately 30 sites across the United States. Participants aged 50 years and older were randomized 1:1:1 to receive a single dose of VAX-31, PCV20 or PCV21 on Day 1. Participants aged 18-49 years were randomized 3:1 to receive a single dose of VAX-31 or PCV20 on Day 1, with PCV20 serving as the safety comparator. Immune responses were assessed one month after vaccination. Safety and tolerability are assessed for six months following vaccination. Additional information about the study can be found at www.clinicaltrials.gov under the identifier NCT07284654.

Key Topline Study Results

Safety and Tolerability Findings:

• VAX-31 was well tolerated and demonstrated a safety profile similar to PCV20 and PCV21 across all ages studied.
• Frequently reported solicited local and systemic reactions, assessed from Day 1 through Day 7, were generally mild-to-moderate, with the majority resolving within 48 hours of vaccination, and with no meaningful differences observed across the cohorts.
• No serious adverse events were considered to be related to study vaccines, and there were no study discontinuations due to adverse events.

Immunogenicity Findings:
Prespecified co-primary immunogenicity endpoints in adults 50 and older:

• For the 11 serotypes in common with PCV20 and PCV21, VAX-31 met 11 of 11 serotype OPA GMR comparisons per the prespecified noninferiority criterion⁴ (LBCI >0.667) compared to PCV20 and/or PCV21.³
• For the nine serotypes in common with PCV20 only, VAX-31 met 9 of 9 serotype OPA GMR comparisons per the prespecified noninferiority criterion⁴ (LBCI >0.667).
• For the eight serotypes in common with PCV21 only, VAX-31 met 8 of 8 serotype OPA GMR comparisons per the prespecified noninferiority criterion⁴ (LBCI >0.667).
• For the three unique serotypes and cross-reactive serotype 20B, VAX-31 met 4 of 4 serotype OPA GMR comparisons per the prespecified superiority criterion⁸ (LBCI >2.0) compared to PCV20 and/or PCV21.³

Prespecified primary immunobridging in adults aged 18-49:

• For all 32¹ serotype OPA GMR comparisons, VAX-31 met the noninferiority criterion (LBCI >0.667) in adults aged 18-49 compared to adults aged 50-64.

Prespecified individual noninferiority comparisons to PCV20 and PCV21:

• Compared to PCV20: VAX-31 OPA GMRs met the prespecified noninferiority criterion (LBCI >0.667)⁴ for 20 of 20 serotypes in common.
• Compared to PCV21: VAX-31 OPA GMRs met the prespecified noninferiority criterion (LBCI >0.667)⁴ for 17 of 19 serotypes in common. Serotypes 3 and 12F missed the LBCI >0.667 noninferiority criterion and met the historical LBCI >0.5 threshold.²

Key Anticipated PCV Franchise Milestones
Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key milestones, including:

VAX-31 Adult Indication

• Announce safety, tolerability and immunogenicity data from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of 2027.

VAX-31 Infant Indication

• Announce topline safety, tolerability and immunogenicity data from the VAX-31 infant Phase 2 randomized, dose-finding study from both the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027.

Conference Call and Webcast
Vaxcyte will hold a webcast and conference call today, October 5, 2026, at 8:00 a.m. ET / 5:00 a.m. PT to discuss the results from OPUS-1. To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX1005. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com. After the live webcast, the event will remain archived on the Vaxcyte website for 30 days.

About Pneumococcal Disease
Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media and sinusitis. In the United States, pneumococcal pneumonia is estimated to result in approximately 225,000 adult hospitalizations each year. Streptococcus pneumoniae is among the World Health Organization’s top antibiotic-resistant pathogens to be urgently addressed, and the U.S. CDC lists drug-resistant Streptococcus pneumoniae as a “serious threat.” In children under five, Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally. Pneumococci also cause over 50% of all cases of bacterial meningitis in the United States. Antibiotics are used to treat PD, but some strains of the bacteria have developed resistance to treatments. The morbidity and mortality due to PD are significant, particularly for young children and older adults, underscoring the need for a broader-spectrum vaccine.

About VAX-31
VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is designed to prevent serious and sometimes fatal infections caused by Streptococcus pneumoniae, including IPD, pneumonia and otitis media. Specifically, IPD is associated with high case-fatality rates, antibiotic resistance and meningitis. VAX-31 is the broadest-spectrum PCV candidate in the clinic today and has the potential to provide protection against both currently circulating and historically prevalent serotypes. VAX-31 is designed to increase coverage, in a single vaccine, to approximately 95% of IPD⁵ and approximately 88% of pneumococcal pneumonia⁶ circulating in adults in the United States aged 50 and older. This disease coverage has the potential to result in VAX-31 providing an incremental 13-36% of coverage for IPD and an incremental 19-31% of coverage for pneumococcal pneumonia over current standard-of-care adult PCVs. In U.S. children, VAX-31 is designed to cover approximately 91% of IPD⁹ and approximately 96% of acute otitis media¹⁰ due to Streptococcus pneumoniae. This disease coverage has the potential to result in VAX-31 providing an incremental 27-47% of coverage for IPD and an incremental 35-62% of coverage for otitis media over current standard-of-care infant PCVs.

In May 2025, the FDA expanded the Breakthrough Therapy designation (BTD) for VAX-31 to include the prevention of pneumonia caused by Streptococcus pneumoniae in addition to the prevention of IPD in adults based on the positive topline results from the VAX-31 adult Phase 1/2 study.

About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.

VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF^®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and vaccine candidates, including breadth of coverage, the ability to deliver potentially best-in-class vaccines and improve upon the standard-of-care; the design, timing of initiation, progress and expected results of Vaxcyte’s clinical trials and regulatory plans along with the standards for review and licensure of vaccines and regulators accepting our study as designed; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “plan,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com

Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com

¹ 31 vaccine serotypes plus cross-reactive serotype 20B.
² In the prespecified individual comparator-specific noninferiority assessments of VAX-31 vs PCV21, the lower bounds of the 95% confidence intervals for the OPA GMRs for serotypes 3 and 12F exceeded >0.5 but did not meet the prespecified individual noninferiority criterion of LBCI >0.667. The historical LBCI >0.5 noninferiority comparison was a prespecified key secondary endpoint.
³ Under the prespecified Hochberg multiplicity adjustment, each of the 11 shared-serotype noninferiority assessments and each of the four primary superiority assessments succeeds against PCV20 and/or PCV21 if the one-sided adjusted p-value is <0.025 against at least one comparator. The OPA GMR margin for primary endpoints is >0.667 for noninferiority and 2.0 for superiority.
⁴ For individual comparator-specific noninferiority assessments and the primary immunobridging assessment, the lower bound of the 95% confidence interval (LBCI) for the opsonophagocytic activity (OPA) geometric mean ratio (GMR) must exceed 0.667 to establish noninferiority.
⁵ Vaxcyte estimates using CDC 2022–2024 Active Bacterial Core surveillance data for U.S. adults aged 50 years and older. Cases with missing serotype data were excluded; non-typeable cases were included in the denominator. The estimates assume cross-protection between serotypes 6A/6C and 15B/15C. https://data.cdc.gov/d/qvzb-qs6p.
⁶ King LM, et al. Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines. J Infect Dis. 2025;232(4):e609–e620. https://doi.org/10.1093/infdis/jiaf376. Vaxcyte estimates use a weighted average of inpatient pneumonia cases in adults aged 50–64 and ≥65 years and assume cross-protection between serotypes 6A/6C and 15B/15C.
⁷ Pneumococcal-naïve means no known history of invasive pneumococcal disease, pneumococcal pneumonia or receipt of a licensed or investigational pneumococcal vaccine.
⁸ LBCI >2.0 for individual comparator-specific superiority assessments. See footnote 3 for the multiplicity-adjusted primary superiority analysis.
⁹ Vaxcyte estimate using CDC 2022–2024 Active Bacterial Core surveillance data for U.S. children under five years of age. Cases with missing serotype data were excluded; non-typeable cases were included in the denominator. The estimate assumes cross-protection between serotypes 6A/6C and 15B/15C. https://data.cdc.gov/d/qvzb-qs6p.
¹⁰ Vaxcyte estimate based on 2017–2021 serotype data for U.S. children five years of age or younger in Supplemental Table 1 of Grant LR, et al. Characterization of Streptococcus pneumoniae isolates obtained from the middle ear fluid of US children, 2011–2021. Front Pediatr. 2024;12:1383748. https://doi.org/10.3389/fped.2024.1383748. The estimate assumes cross-protection between serotypes 6A/6C and 15B/15C.